chrisvoncsefalvay/vaers-outcomes huggingface dataset:
It was reported that a pt (3 of 4) received a Fluzone 2000-2001 vaccination, given IM on 10/19/2000. Reportedly the pt developed numbness and tingling in the arm and hand after the injection. No specifics were provided. Further information is being requested. From additional correspondence received on 03/16/2001, it was reported mild relieved with ice packs. The pt reportedly recovered from this experience. Additional responsible facility, vaccine and pt information was provided.
I26.99 ACUTE PULMONARY EMBOLISM 12/11/2021 HEMATURIA J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 12/11/2021 HEMATURIA I26.99 ACUTE PULMONARY EMBOLISM 12/11/2021 RIGHT FEMORAL NECK UNSPECIFIED TYPE FX, INIT J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 12/11/2021 RIGHT FEMORAL NECK UNSPECIFIED TYPE FX, INIT I26.99 ACUTE PULMONARY EMBOLISM 12/11/2021 ATRIAL FIBRILLATION, UNSPECIFIED J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 12/11/2021 ATRIAL FIBRILLATION, UNSPECIFIED
Fever rush(up to 38.2 Celsius for a night) with severe muscle pain and fast heart rate(110+ bpm). Began after the second dose from 01:00 to 06:00.
pt recv vax & devel lateral arm discomfort & shoulder tenderness, no erythema, no swelling;pain not @ site but in arm & shoulder, same side as inj;
Information has been received from a physician referring to a patient of unknown age and gender. No relevant medical history or concurrent conditions were reported. On an unknown date the patient was vaccinated with GARDASIL (lot#, expiration date, dose and route not reported). On an unknown date the patient experienced Lyme's disease after receiving GARDASIL. The outcome of the event was unknown. Causality assessment was not reported. Additional information has been requested.
Soreness and swelling at injection site (left arm) for over two days. Fever the night of the vaccine.  Woke with sore neck and back and a headache. Day after the vaccine shortness of breath and increased hear rate began. For 9 days after the vaccine I was short of breath with increased heat rate doing anything but sitting or laying. I was out of breath walking across a room and gasping after going up stairs. Exhausted/ fatigued for 9 days after vaccine with increased sleep (naps, bed early) and speaking was slow and occasionally labored. Right eye was constantly twitching and both legs had tingles for several days after vaccine. Small, quick chest pains for 9 days.
I caught the flu; Initial information received on 18-Nov-2022 regarding an unsolicited valid Social Media non-serious case received from a consumer/non-hcp.  This case involves Adult and unknown gender patient who caught the flu after receiving Influenza vaccine.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient caught the flu (influenza) after receiving an unknown dose of suspect Influenza vaccine produced by unknown manufacturer lot number not reported via unknown route in unknown administration site for Influenza immunization with unknown form, strength, frequency, expiry date.  Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the event (I caught the flu ).  Outcome: Unknown.
A non serious report of "gave FLUMIST to an 11-month-old" has been received from a registered nurse concerning an 11-month-old male. Medical history and concomitant medications were not reported, There was no adverse event associated with this medication error; therefore, treatment and reporter/sponsor causality assessments are not applicable, and the event is considered resolved, This case is admitted in accordance with a post-marketing commitment on accelerated reporting for the newly indicated population of 2 years to 59 months of age for FLUMIST. Additional information received on 24-Dec-2008 was incorporated into the narrative and included the patient's gender. The reporting nurse confirmed that there were no late-occurring adverse events.
pt recv vax OCT96 & 13DEC96 pt exp a fever of 100.4, malaise, myalgia & hacking cough w/yellow sputum;pt missed 3 days of work d/t sx;pt has not yet recovered as of 18DEC96;MD 7FEB97 revealed that pt exp fever, chills,body aches, cough;
8/3/08 - Itching, burning, blisters on one side of face and eyelid.  Seen by opthamologist and treated with Valtrex for diagnosis of Shingles.
Some localized itching after vaccination. Also, funny taste in mouth. Developed a silver dollar size red spot on L-arm at injection area the following day. Itching is not persistent.
Inflammation in the back; Barely sleep at night; Feels like there is a knot in her back; Back pain for 3 or 4 days; This spontaneous case was reported by a consumer and describes the occurrence of INFLAMMATION (Inflammation in the back), INSOMNIA (Barely sleep at night), MASS (Feels like there is a knot in her back) and BACK PAIN (Back pain for 3 or 4 days) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 002C21A and 022B21A) for COVID-19 vaccination.     Concurrent medical conditions included Penicillin allergy and Sulfonamide allergy (sulfa drugs). Concomitant products included VITAMIN B NOS, VITAMIN D NOS and VITAMINS NOS (MULTIVIT [VITAMINS NOS]) for an unknown indication.   On 24-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 24-Apr-2021, the patient experienced BACK PAIN (Back pain for 3 or 4 days). On an unknown date, the patient experienced INFLAMMATION (Inflammation in the back), INSOMNIA (Barely sleep at night) and MASS (Feels like there is a knot in her back). On 28-Jul-2021, BACK PAIN (Back pain for 3 or 4 days) had resolved. At the time of the report, INFLAMMATION (Inflammation in the back), INSOMNIA (Barely sleep at night) and MASS (Feels like there is a knot in her back) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, X-ray: normal (normal) Normal..     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient took a "muscle relaxers" and an anti-inflammatory medication for treatment.   This case was linked to MOD-2021-270722 (Patient Link).
Had fever and then had approx. 10 min episode of head back and unresponsive - probable seizure.
According to Mother -patient developed fever 101,vomiting x5, diarrhea x1.
Patient is fully vaccinated.  COVID + on 11/20/2021.  Hospitalized from 11/20-12/1, 2021.  76-year-old gentleman with significant past medical history for back pain/COPD/coronary artery disease, who presented due to complaint of shortness of breath;requiring 4 L of O2, denied any chest pain/fevers/chills; He also complains of subjective fever reaching 102. Admitting dx: SOB, Hypoxia, COVID-19, afib with RVR.  CXR Suspected persistent congestion with progressive infiltrative findings on left.D-dimer 321--350--378-- 563--1017--390, downtrend/  Heparin, cardizem, eliquis for new afib.  Bradycardia, help remdisivir. hypomagnesemia with replacement. Discharged to home.
Subsequent to receiving varicella virus vaccine live the pt broke out in a rash all over body. Diagnosed as urticaria rash all over his body.
Low grade fever, body aches, lightheadedness and sore arm. Developed a localized rash that was later diagnosed as shingles on 01/11/2021 by her PCP. A 01/04/202 COVID test was negative.
Information has been received from a registered nurse concerning a 38 year old female with asthma and a gastrointestinal intolerance to erythromycin who on 4/8/04 was vaccinated with varicella virus vaccine live (lot # 643823/0869M). Concomitant therapy included montelukast sodium and fluticasone propionate (+) salmeterol xinafoate. There was no illness at the time of vaccination. The RN reported that, two weeks later, on approximatley 4/22/04, the patient developed hardness at the injection site as well as silver dollar redness, soreness and swelling at the injection site with body aches. Unspecified medical attention was sought. In April 2004, 24 to 48 hours following the initiation of azithromycin, the patient's events were considered to be resolved. No further information is expected.
At 6 days after treatment I developed a hard red path about 5'" x 3" on injection arm. It itched and burned for 3 days
pt recv vax 21OCT97 p/nail injury;pt had redness, swelling, sore arm, sl temp for 3 days p/vax; on day 8 pt devel 5 1/2" x 4 1/2 area of erythema w/itching, burning & swelling;
3:20 pt reports tingling in lips and nasal area. Pt states this is not the first time I have had this happen it happened in the past with flu and pneumonia vaccines. Pt denies chest tightness, throat irriration or wheezing. Pt is alert and oriented x3 and is up walking. Pt instructed to wait 15mins and will reassess. 3:35pm rechecked and s/s worsening. 3:37pm Benadryl 25mg po liquid given.  3:45pm pt states feeling better still some tingling. Pt instructed to continue to stay in clinic until tingling is completely resolved. 3:50pm Clinic Manager informed of patient reaction and treatment given. 3:55pm pt reports small area of tingling in center of bottom lip. 4:00pm Medical Health Officer for County Health Dept informed of patient reaction and treatment. She requested skin assessment and complete vital signs.  4:05pm upon returning to waiting room, client was not present. Per patient service representative client left building with husband at 4:00pm.
A non-serious spontaneous report of cold has been received from a consumer concerning her daughter, a 36-month-old female, subsequent to FLUMIST. This case will be submitted in accordance with MedImmune's FLUMIST post-marketing commitment for the indicated population of 2 years to 60 months of age. Patient has no medical history or concomitant medications. The patient received FLUMIST in 2009. The reporter stated that she and her daughter developed cold after receiving FLUMIST. The patient was not hospitalized. The outcome of the event was resolved. Additional information received on 11-MAY-2011 and incorporated into case, modification of event term from flu to cold, outcome, concomitant medications, and medical history.
Shortly after I received the 1st dose I started itching on the back of my head and 2 or 3 days later after the 2nd dose I started breaking out in hives.
pt recv vax & devel pain & stiffness has greatly inc in severity;now includes rt shoulder, feet, knees;
below freezing temperature excursion; This case was reported by a physician via call center representative and described the occurrence of incorrect storage of drug in a 15-year-old male patient who received HAV (Havrix) (batch number yl532, expiry date 9th September 2022) for prophylaxis.   On 16th July 2021, the patient received Havrix. On an unknown date, unknown after receiving Havrix, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown.  Additional details were provided as follows: The physician reported that a patient was administrated with Havrix after a belowfreezing temperature excursion, which led to  incorrect storage of drug No adverse event was reported. The reporter consented to follow up. This case is linked with one of the many cases, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021164775:same reporter US-GLAXOSMITHKLINE-US2021164802:same reporter US-GLAXOSMITHKLINE-US2021164789:same reporter US-GLAXOSMITHKLINE-US2021164788:same reporter US-GLAXOSMITHKLINE-US2021164781:same reporter US-GLAXOSMITHKLINE-US2021164787:same reporter US-GLAXOSMITHKLINE-US2021164792:same reporter US-GLAXOSMITHKLINE-US2021164791:same reporter US-GLAXOSMITHKLINE-US2021164783:same reporter US-GLAXOSMITHKLINE-US2021164777:same reporter US-GLAXOSMITHKLINE-US2021164779:same reporter US-GLAXOSMITHKLINE-US2021164800:same reporter US-GLAXOSMITHKLINE-US2021164771:same reporter US-GLAXOSMITHKLINE-US2021164801:same reporter US-GLAXOSMITHKLINE-US2021164784:same reporter US-GLAXOSMITHKLINE-US2021164769:same reporter US-GLAXOSMITHKLINE-US2021164786:same reporter US-GLAXOSMITHKLINE-US2021164794:same reporter US-GLAXOSMITHKLINE-US2021164795:same reporter US-GLAXOSMITHKLINE-US2021164798:same reporter US-GLAXOSMITHKLINE-US2021164797:same reporter US-GLAXOSMITHKLINE-US2021164799:same reporter US-GLAXOSMITHKLINE-US2021164804:same reporter US-GLAXOSMITHKLINE-US2021164803:same reporter US-GLAXOSMITHKLINE-US2021164805:same reporter US-GLAXOSMITHKLINE-US2021164806:same reporter US-GLAXOSMITHKLINE-US2021164808:same reporter US-GLAXOSMITHKLINE-US2021164795:Same reporter.
a person who has received the covid vaccine but tested positive to the infection; a person who has received the covid vaccine but tested positive to the infection; This is a spontaneous report from a contactable pharmacist. This pharmacist reported that an 85-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number unknown) intramuscular at single dose on 21Jan2021 for COVID-19 immunisation. The patient received the first dose on unknown date. Relevant history and concomitants drugs were not reported. Per reporter, the patient was not seeing anything crazy on her chart. The patient got the second dose of the COVID vaccine on 21Jan2021. On 22Jan2021, she had been tested positive for COVID-19 (COVID-19 Rapid test).  The patient had cough and low grade fever since unknown date. Relevant test was none. Outcome of event was unknown. The nurse practitioner wanted to do a monoclonal antibody infusion and the pharmacist was wondering if they could do that?   When probed for causality, the pharmacist responded: "I guess not I'm not going to comment on that, I don't know. I don't have the patient's actual file."  Information on the Lot/Batch number has been requested.; Sender's Comments: Based on the information currently available, lack of efficacy of the suspected vaccine BNT162B2 cannot be completely excluded. However, individuals may not be protected until at least 7 days after their second dose of the vaccine. It is unlikely that the patient would have fully developed immunity due to the very short time lag between the second vaccine dose and the event onset.
Narrative:  78 y/o Male with HIV, Multiple Myeloma on chemo, HTN, paroxysmal SVT, COPD and active smoker, chronic kidney disease, peripheral neuropathy, PVD. Patient recently discharged from hospital 10/31/21. At that time was admitted and treated for septic shock from e-coli bacteremia and e coli pneumonia. He was intubated, on broad spectrum abx and on pressors. Blood cultures grew 2/2 E coli and also growth in BAL. He completed a 2 week course of IV antibiotics and was discharged to a nursing facility. At that time he was COVID negative. He was also previously covid vaccinated and s/p booster. While at the nursing facility he was noted to have cough, SOB, hypoxia and low BP's. He admits to also having headache, loss of taste and smell, cough with clear sputum, SOB, fever/chills and body aches. For that reason he presented back to the ED. Patient id fully Covid vaccinated (With Booster) with PMH of HIV on HAART, multiple myeloma on chemo (lenalidomide, decadron last 10/8/21), essential hypertension, paroxysmal SVT, COPD not on HOT h/o s/p Intubation 10/2021(AHRF from sepsis), tobacco dependency, recently discharged 11/04/2021 to Care Center transferred to ED for Cough and SOB,loss of sense of taste & smell x 1 week ,O2 sat at 2 LPM NC 91%,COVID +,CTA Chest : no PE ,+GGO ,CXRAY: Neg,BP 99/59 , serum procalcitonin :0.22. Patient while in hospital continue to deteriorate and develop leukocytosis with white blood cell count of 20,000 started empirically on IV Zosyn however his respiratory status continued to worsen. His overall physical endurance has deteriorated and eventually patient requesting to be placed in end of life hospice/palliative care (12/07/2021). Patient is awaiting transfer to an inpatient hospice center.
Area of redness measuring 70mmx80mm; itchy, tenderness/pain at site, heat.
Moderna COVID-19 Vaccine EUA Pain, swelling, redness at the injection site started anew 7 days after the vaccine was received. The area was indurated.  Also low grade fever.  Diagnosed as cellulitis, being treated with oral course of Doxycycline.
This spontaneous report as received from a pharmacist refers to unspecified number of patients of unknown age and gender. On an unknown date, the patients were vaccinated with improperly stored ZOSTAVAX lot # K015308, expiration date 17-DEC-2015 (route and site of administration were not reported). No adverse effects were reported. Additional information has been requested.
Patient called office 3-4 hours following vaccine administration c/o blurred vision, feeling extremely tired/lethargic, and pain at the site - of which she had never previously experienced.
did not receive full second dose; did not receive full second dose; This spontaneous case was reported by a health care professional and describes the occurrence of UNDERDOSE (did not receive full second dose) and DEVICE CONNECTION ISSUE (did not receive full second dose) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 006C21A and 049C21A) for COVID-19 vaccination.     No medication history was provided.    On 27-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1. On 26-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 2. On 26-May-2021, the patient experienced UNDERDOSE (did not receive full second dose) and DEVICE CONNECTION ISSUE (did not receive full second dose). At the time of the report, UNDERDOSE (did not receive full second dose) and DEVICE CONNECTION ISSUE (did not receive full second dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication use was unknown
This case was reported by a pharmacist and described the occurrence of wrong vaccine administered in a patient who received TWINRIX. Co-suspect products included HAVRIX and ENGERIX B. On an unknown date, the patient received the 1st dose of TWINRIX, the 2nd dose of HAVRIX and the 2nd dose of ENGERIX B. On an unknown date, an unknown time after receiving TWINRIX, HAVRIX and ENGERIX B, the patient experienced wrong vaccine administered and inappropriate schedule of vaccine administered. On an unknown date, the outcome of the wrong vaccine administered and inappropriate schedule of vaccine administered were unknown. It was unknown if the reporter considered the wrong vaccine administered and inappropriate schedule of vaccine administered to be related to TWINRIX, HAVRIX and ENGERIX B. Additional information: It was an incorrect schedule for TWINRIX. Wrong vaccines given: ENGERIX B and HAVRIX. The patient received TWINRIX as dose 1 and ENGERIX B and HAVRIX as dose 2. No adverse event reported.
The adverse reaction began within hours of the vaccine.  It began with flu like symptoms including chills, fatigue, and aches (no fever but Patience rarely runs a fever even if very ill).  Aches included sharp pains in her right calf muscle.  Flu like symptoms persisted for 5 days and began subside on the 6th day.  Patience was able to return to work on the 9th day, although pain in her right leg persisted.  Over the next several weeks she had a VQ lung scan, bilateral Doppler ultra sounds of both legs, and chest x-ray as well as an array of blood work   which were all negative.  The pain continued to worsen to the point where she was not able to walk or drive.  She visited an orthopedic urgent care center for evaluation, where it was suggested a nerve in her back was causing the pain.  She was prescribed Gabapentin and refereed to Physical Therapy and a back specialist.  Because there was a long wait to get an appointment with the back specialist, and the pain was worsening, she went to a different orthopedist who took x-rays and MRI of the leg, as well as additional blood tests.  The X-ray showed no breaks or injuries to the bone, and the MRI showed no soft tissue damage but it did show some minor inflamation of the muscle.  Her labs were all normal except for a slightly elevated C-Reactive Protein and slightly low Hemoglobin.  The orthopedist prescribed a boot and recommended rest and continued Gabapentin.  Over the next three weeks the pain subsided.  With the MRI results showing no bone damage, she discontinued the boot, and with no remarkable spine abnormalities she discontinued the Gabapentin, and is currently taking a combination of Tylenol and Advil, and has returned to work on a reduced schedule.  The pain has subsided but is still present and flares up at times.  She is starting to experience similar symptoms on the left leg.  The treating Orthopedist has referred her to a Rheumatologist, appointment is pending as of this date
LPN who administered the vaccine went into the vial more than 20 times.  No untoward effects to patient arm.  MD was made aware and evaluated the patient.
Itching at the injections site; erythema at injection site; induration at the injection site spreading over the proximal arm; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE INFLAMMATION (nflammation at injection site), VACCINATION SITE INDURATION (induration at the injection site spreading over the proximal arm), VACCINATION SITE PRURITUS (Itching at the injections site) and VACCINATION SITE ERYTHEMA (erythema at injection site) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE INFLAMMATION (nflammation at injection site), VACCINATION SITE INDURATION (induration at the injection site spreading over the proximal arm), VACCINATION SITE PRURITUS (Itching at the injections site) and VACCINATION SITE ERYTHEMA (erythema at injection site). At the time of the report, VACCINATION SITE INFLAMMATION (nflammation at injection site), VACCINATION SITE INDURATION (induration at the injection site spreading over the proximal arm) and VACCINATION SITE ERYTHEMA (erythema at injection site) had resolved and VACCINATION SITE PRURITUS (Itching at the injections site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications were not provided. The patient did not receive any treatment medications.
I woke around 04:30AM, I was dizzy, I felt like I was going to throw up and have diarrhea. I called my boyfriend to have him unlock the door. I called 911 and have the ambulance come and transport me to the hospital. Once I arrived at the hospital, they did a CT scan that came back normal, my blood pressure was normal, they did an MRI that came back not normal, and they felt I was having a MS flare in my brain. They admitted me for two days so they I could have the IV therapy of steroids to help calm the inflammation in the brain. They also needed to keep an eye on my blood sugar as the high doses of steroids cold increase my that. I am now back to work, working from home full time.
pt recv vax & exp site bleeding sm amt when needle w/drawn; pressure & bandaid applied; called mom on 28APR95 & leg was fine; mom presented w/pt on 1MAY95 to clinic; tennis ball size swelling @ inj site w/sm redness @ inj site;